Novartis licenses Arvinas' cancer drug for up to $1 billion

Arvinas

11/04/2024 12:17

April 11 (Reuters) - Swiss drugmaker Novartis AG
 NOVN.S  has entered into a licensing deal worth up to $1.01
billion with Arvinas  ARVN.O  for the U.S. drug developer's
experimental prostate cancer drug, Arvinas said on Thursday.   

 (Reporting by Mariam Sunny in Bengaluru; Editing by Shailesh
Kuber)
 ((Mariam.ESunny@thomsonreuters.com;))